Loading clinical trials...

UNKNOWNPHASE2

Lazertinib 160mg in EGFR T790M NSCLC

A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer

NCT05701384•Samsung Medical Center

View on ClinicalTrials.gov

Summary

The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically confirmed non-small cell lung cancer
•Patients in a palliative setting who is not applicable for the curative treatment
•EGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKI
•Confirmed EGFR T790M mutation after the previous EGFR TKI
•Available to receive lazertinib either as po or vis levine tube
•Willing to participate clinical trial
•Age over or equal to 19
•ECOG PS 0 to 2

Exclusion Criteria

•Previously received 3rd generation EGFR TKI
•No clinical benefit is expected based on the investigator's decision
•Uncontrolled symptomatic CNS metastases
•Uncontrolled systemic disease

Locations (1)

Samsung Medical Center

Seoul, MA, South Korea

Key Dates

Start Date

February 1, 2023

Primary Completion Date

January 31, 2024

Completion Date

January 31, 2025

Last Updated

January 27, 2023

Enrollment

117

ESTIMATED participants

Conditions

Lung Cancer Stage IVEGFR T790M

Interventions

Lazertinib

DRUG

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477

Non-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IV+3 more

View study

RECRUITINGEARLY_PHASE1

[177Lu]Lu-AKIR001 First-in-human Study

NCT06639191

Thyroid Gland Anaplastic CarcinomaPoorly Differentiated Thyroid Carcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lazertinib 160mg in EGFR T790M NSCLC

Inclusion Criteria

Exclusion Criteria

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

[177Lu]Lu-AKIR001 First-in-human Study

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System

Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer